EyePoint (EYPT) Stock Price

EyePoint Price

NASDAQ·CLOSED
14.72USD-0.12 (-0.81 %)
Market closed

Revenue has compounded at 25.0% per year over the past 19 years to 43.27 M USD. EyePoint's net margin stands at -302.4%, down from -131.8% several years earlier. Analysts set a median price target of 33.66 USD, implying 128.7% above the current price. Of 18 analysts, 17 rate the stock a buy — an overall Buy consensus. The stock trades about 52% above its 52-week low.

EyePoint stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of EyePoint over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how EyePoint stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing EyePoint's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

EyePoint Stock Price History
DateEyePoint Price
7/10/202614.72 USD
7/9/202614.84 USD
7/8/202614.23 USD
7/7/202614.02 USD
7/6/202614.20 USD
7/2/202613.98 USD
7/1/202613.19 USD
6/30/202614.30 USD
6/29/202613.88 USD
6/26/202613.66 USD
6/25/202613.71 USD
6/24/202614.40 USD
6/23/202614.38 USD
6/22/202613.57 USD
6/18/202613.41 USD
6/17/202613.32 USD
6/16/202612.32 USD
6/15/202613.07 USD
6/12/202612.77 USD
6/11/202612.48 USD
6/10/202612.17 USD
6/9/202611.77 USD
6/8/202611.45 USD
6/5/202611.95 USD
6/4/202612.70 USD
6/3/202612.34 USD
6/2/202612.35 USD
6/1/202612.88 USD
5/29/202613.74 USD
5/28/202613.87 USD
5/27/202612.99 USD
5/26/202612.78 USD
5/22/202613.33 USD
5/21/202612.83 USD
5/20/202612.63 USD
5/19/202611.82 USD
5/18/202611.70 USD
5/15/202612.35 USD
5/14/202613.24 USD
5/13/202613.43 USD
5/12/202613.62 USD
5/11/202613.98 USD
5/8/202613.66 USD
5/7/202613.41 USD
5/6/202613.35 USD
5/5/202613.75 USD
5/4/202613.85 USD
5/1/202613.34 USD
4/30/202613.20 USD
4/29/202612.86 USD
4/28/202613.47 USD
4/27/202613.60 USD
4/24/202613.77 USD
4/23/202613.84 USD
4/22/202614.24 USD
4/21/202614.11 USD
4/20/202615.07 USD
4/17/202614.93 USD
4/16/202614.81 USD
4/15/202614.63 USD
4/14/202614.34 USD
4/13/202614.52 USD
4/10/202614.19 USD
4/9/202614.23 USD
4/8/202614.17 USD
4/7/202613.57 USD
4/6/202613.11 USD
4/2/202613.40 USD
4/1/202613.02 USD
3/31/202612.89 USD
3/30/202611.85 USD
3/27/202612.50 USD
3/26/202613.06 USD
3/25/202613.05 USD
3/24/202612.59 USD
3/23/202612.83 USD
3/20/202613.23 USD
3/19/202613.79 USD
3/18/202613.64 USD
3/17/202613.90 USD
3/16/202613.45 USD
3/13/202613.20 USD
3/12/202614.03 USD
3/11/202614.92 USD
3/10/202615.44 USD
3/9/202615.67 USD
3/6/202615.75 USD
3/5/202615.76 USD
3/4/202618.00 USD
3/3/202618.32 USD
3/2/202618.34 USD
2/27/202617.56 USD
2/26/202617.86 USD
2/25/202617.76 USD
2/24/202617.05 USD
2/23/202617.07 USD
2/20/202615.33 USD
2/19/202614.70 USD
2/18/202614.36 USD
2/17/202614.91 USD
2/13/202612.94 USD
2/12/202613.01 USD
2/11/202612.85 USD
2/10/202613.72 USD
2/9/202614.07 USD
2/6/202613.30 USD
2/5/202612.73 USD
2/4/202612.33 USD
2/3/202612.80 USD
2/2/202613.29 USD
1/30/202613.52 USD
1/29/202614.75 USD
1/28/202615.04 USD
1/27/202615.81 USD
1/26/202615.45 USD
1/23/202615.18 USD
1/22/202616.34 USD
1/21/202615.53 USD
1/20/202615.54 USD
1/16/202615.08 USD
1/15/202615.84 USD
1/14/202615.92 USD
1/13/202615.93 USD
1/12/202615.94 USD
1/9/202616.23 USD
1/8/202617.08 USD
1/7/202617.37 USD
1/6/202616.86 USD
1/5/202617.43 USD
1/2/202617.48 USD
12/31/202518.27 USD
12/30/202517.89 USD
12/29/202518.20 USD
12/26/202518.29 USD
12/24/202518.26 USD
12/23/202518.38 USD
12/22/202518.85 USD
12/19/202517.43 USD
12/18/202517.06 USD
12/17/202516.66 USD
12/16/202516.93 USD
12/15/202516.40 USD
12/12/202515.99 USD
12/11/202516.10 USD
12/10/202516.72 USD
12/9/202517.08 USD
12/8/202517.82 USD
12/5/202517.74 USD
12/4/202516.72 USD
12/3/202514.52 USD
12/2/202513.69 USD
12/1/202514.26 USD
11/28/202514.83 USD
11/26/202514.79 USD
11/25/202514.74 USD
11/24/202514.40 USD
11/21/202513.68 USD
11/20/202513.64 USD
11/19/202514.28 USD
11/18/202513.96 USD
11/17/202513.14 USD
11/14/202511.58 USD
11/13/202511.51 USD
11/12/202511.99 USD
11/11/202511.65 USD
11/10/202511.35 USD
11/7/202511.21 USD
11/6/202511.08 USD
11/5/202511.02 USD
11/4/202512.39 USD
11/3/202512.45 USD
10/31/202513.09 USD
10/30/202512.21 USD
10/29/202511.73 USD
10/28/202512.25 USD
10/27/202512.11 USD
10/24/202511.98 USD
10/23/202511.50 USD
10/22/202511.45 USD
10/21/202511.81 USD
10/20/202512.03 USD
10/17/202511.63 USD
10/16/202511.55 USD
10/15/202511.73 USD
10/14/202513.16 USD
10/13/202513.34 USD
10/10/202513.57 USD
10/9/202513.98 USD
10/8/202513.88 USD
10/7/202513.25 USD
10/6/202513.62 USD
10/3/202513.73 USD
10/2/202513.50 USD
10/1/202512.92 USD
9/30/202514.24 USD
9/29/202514.05 USD
9/26/202513.90 USD
9/25/202513.19 USD
9/24/202514.08 USD
9/23/202513.39 USD
9/22/202513.36 USD
9/19/202513.25 USD
9/18/202513.76 USD
9/17/202513.64 USD
9/16/202513.60 USD
9/15/202513.41 USD
9/12/202513.35 USD
9/11/202513.33 USD
9/10/202513.55 USD
9/9/202514.19 USD
9/8/202513.65 USD
9/5/202514.01 USD
9/4/202511.88 USD
9/3/202512.00 USD
9/2/202511.73 USD
8/29/202511.57 USD
8/28/202511.60 USD
8/27/202511.84 USD
8/26/202512.04 USD
8/25/202511.59 USD
8/22/202511.83 USD
8/21/202511.60 USD
8/20/202511.51 USD
8/19/202511.04 USD
8/18/202511.33 USD
8/15/202511.09 USD
8/14/202510.85 USD
8/13/202511.01 USD
8/12/202510.75 USD
8/11/202510.28 USD
8/8/202510.23 USD
8/7/202510.07 USD
8/6/202510.58 USD
8/5/202510.89 USD
8/4/202510.06 USD
8/1/20259.71 USD
7/31/20259.82 USD
7/30/20259.84 USD
7/29/20259.85 USD
7/28/202510.03 USD
7/25/202510.48 USD
7/24/202510.49 USD
7/23/202510.70 USD
7/22/202510.45 USD
7/21/202510.54 USD
7/18/202510.42 USD
7/17/202510.30 USD
7/16/202510.06 USD
7/15/20259.84 USD
7/14/202510.17 USD
Access this data via the Eulerpool API
Get Free API Key

EyePoint Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
41.40 M USD
-78.94 M USD
-102.25 M USD
Jan 1, 2023
46.02 M USD
-75.07 M USD
-70.80 M USD
Jan 1, 2024
43.27 M USD
-145.85 M USD
-130.87 M USD
Jan 1, 2025 (e)
32.44 M USD
-239.64 M USD
-174.15 M USD
Jan 1, 2026 (e)
9.33 M USD
-272.87 M USD
-167.97 M USD
Jan 1, 2027 (e)
60.46 M USD
-276.04 M USD
-155.43 M USD
Jan 1, 2028 (e)
268.43 M USD
-114.70 M USD
-33.88 M USD
Jan 1, 2029 (e)
617.85 M USD
142.36 M USD
133.22 M USD

EyePoint Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 12, 2026, 7:28 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2016201720182019202020212022202320242025e2026e2027e2028e2029e2030e2031e
–0.01–0.020.030.040.040.050.040.030.010.060.270.620.891.16
-96.15600.00-71.43900.0070.005.8813.8912.20-6.52-25.58-71.88566.67346.67130.2243.9230.86
3,900.00557.141,950.0085.0082.3577.7880.4989.1390.7090.7090.7090.7090.7090.7090.7090.70
0.040.040.040.020.030.030.030.040.040.030.010.050.240.560.811.05
-21.00-18.00-53.00-56.00-45.00-58.00-102.00-70.00-130.00-174.00-167.00-155.00-33.00133.00211.00304.00
-450.00-14.29194.445.66-19.6428.8975.86-31.3785.7133.85-4.02-7.19-78.71-503.0358.6544.08
3.163.534.6210.4312.8428.7637.3238.9056.3056.3056.3056.3056.3056.3056.3056.30
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales EyePoint generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue EyePoint retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare EyePoint's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares EyePoint has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against EyePoint's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

EyePoint stock margins

The EyePoint margin analysis displays the gross margin, EBIT margin, as well as the profit margin of EyePoint. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for EyePoint.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
83.07 %
-106.56 %
-131.79 %
Jan 1, 2021
77.86 %
-149.65 %
-158.15 %
Jan 1, 2022
79.90 %
-190.68 %
-246.98 %
Jan 1, 2023
89.93 %
-163.13 %
-153.84 %
Jan 1, 2024
91.42 %
-337.06 %
-302.43 %
Jan 1, 2025 (e)
91.42 %
-738.68 %
-536.80 %
Jan 1, 2026 (e)
91.42 %
-2,924.38 %
-1,800.13 %
Jan 1, 2027 (e)
91.42 %
-456.59 %
-257.10 %

EyePoint Stock Revenue, EBIT, Earnings per Share

The EyePoint earnings per share therefore indicates how much revenue EyePoint has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
2.68 USD
-2.86 USD
-3.54 USD
Jan 1, 2021
1.28 USD
-1.92 USD
-2.03 USD
Jan 1, 2022
1.11 USD
-2.12 USD
-2.74 USD
Jan 1, 2023
1.18 USD
-1.93 USD
-1.82 USD
Jan 1, 2024
0.77 USD
-2.59 USD
-2.32 USD
Jan 1, 2025 (e)
0.58 USD
-4.26 USD
-3.09 USD
Jan 1, 2026 (e)
0.17 USD
-4.85 USD
-2.98 USD
Jan 1, 2027 (e)
1.07 USD
-4.90 USD
-2.76 USD

EyePoint business model & stock analysis

EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and marketing of innovative products targeting medical and eye-related conditions. The company was founded in 1987 and is headquartered in Watertown, Massachusetts. EyePoint Pharmaceuticals has a diverse portfolio of products focused on the treatment of eye diseases. This includes products for the treatment of retinal diseases such as diabetic retinopathy, macular degeneration, and retinal vein occlusions, as well as products for preventing postoperative infections and relieving pain after eye surgeries. The business model of EyePoint Pharmaceuticals is based on the development and marketing of drugs and technologies tailored to the needs of patients and physicians in the field of ophthalmology. The company aims to improve patients' quality of life by offering innovative, safe, and effective products of the highest quality. One of EyePoint Pharmaceuticals' key technologies is the Durasert technology, which allows for controlled release of drugs over an extended period of time. This technology is utilized in many of the company's products, such as the Iluvien implant for treating diabetic retinopathy and macular degeneration. The company operates in various sectors, including ophthalmology, pain management, and ophthalmology. Each of these sectors has its own products and technologies tailored specifically to the needs of patients and physicians in those areas. A significant factor in EyePoint Pharmaceuticals' business model is partnerships with other companies and organizations that support collaboration in the development and marketing of new products. One such partnership is the joint venture with Ocumension Therapeutics, which aims to market EyePoint Pharmaceuticals' products in the Asian market. Overall, the company has introduced a variety of innovative products to the market that have had a significant impact on ophthalmology. These include products such as the Ozurdex implant for treating macular degeneration and uveitis, as well as the Dexycu injection for preventing postoperative inflammation and pain. In recent years, the company has made progress in the development of drugs for retinal diseases such as diabetic retinopathy and retinal vein occlusions. One such development is the Yutiq implant, specifically designed to slow the progression of diabetic retinopathy. Overall, EyePoint Pharmaceuticals has a significant influence on ophthalmology and plays a crucial role in the development of innovative products and technologies to improve patients' quality of life. The company will continue to play an important role in the medical industry by focusing on the development and marketing of products targeting specific needs of patients and physicians in the field of ophthalmology.

EyePoint SWOT Analysis

Strengths

EyePoint Pharmaceuticals Inc has a strong portfolio of innovative eye care products.

The company has a robust research and development pipeline with potential for future growth and expansion.

EyePoint Pharmaceuticals Inc has a highly experienced and talented team of scientists and researchers.

The company has established strong relationships with key stakeholders, including healthcare professionals and regulatory authorities.

Weaknesses

EyePoint Pharmaceuticals Inc faces intense competition from other players in the eye care industry.

The company's dependence on a few key products for revenue generation increases its vulnerability to market fluctuations.

EyePoint Pharmaceuticals Inc may face challenges in effectively marketing and promoting its products to target customers.

The company's financial performance has been inconsistent in recent years.

Opportunities

Growing elderly population and increasing prevalence of eye-related diseases present a significant market opportunity for EyePoint Pharmaceuticals Inc.

The company can explore partnerships and collaborations to expand its global reach and enter new markets.

Advancements in technology and drug delivery systems offer opportunities for the development of innovative eye care solutions.

EyePoint Pharmaceuticals Inc can leverage its strong R&D capabilities to develop differentiated products and gain a competitive advantage.

Threats

Stringent regulatory requirements and approval processes pose a threat to the timely launch of new products.

Rapidly changing market dynamics and evolving customer preferences can impact the demand for EyePoint Pharmaceuticals Inc's products.

The company may face legal and intellectual property challenges from competitors.

Fluctuating raw material prices can influence the company's production costs and profit margins.

EyePoint Segments

EyePoint Revenue by Segment (1/5)

  • 3 Years

  • 5 Years

  • Max

Product
License and collaboration agreement
Royalty Income
License and Collaboration Agreements
Details
Date
Product
License and collaboration agreement
Royalty Income
License and Collaboration Agreements
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
16.82 M USD
1.36 M USD
2.18 M USD
0.00 USD
Jan 1, 2020
213,000.00 USD
11.50 M USD
1.70 M USD
0.00 USD
Jan 1, 2021
308,000.00 USD
543,000.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
363,000.00 USD
0.00 USD
269,000.00 USD
191,000.00 USD
Jan 1, 2024
500,000.00 USD
0.00 USD
500,000.00 USD
500,000.00 USD
Jan 1, 2025
900,000.00 USD
0.00 USD
400,000.00 USD
100,000.00 USD

EyePoint Revenue by Segment (2/5)

  • 3 Years

  • 5 Years

  • Max

YUTIQ product
YUTIQ
Details
Date
YUTIQ product
YUTIQ
Jan 1, 2018
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
Jan 1, 2020
13.88 M USD
0.00 USD
Jan 1, 2021
16.96 M USD
0.00 USD
Jan 1, 2022
0.00 USD
28.33 M USD
Jan 1, 2024
0.00 USD
3.10 M USD
Jan 1, 2025
0.00 USD
1.60 M USD

EyePoint Revenue by Segment (3/5)

  • 3 Years

  • 5 Years

  • Max

DEXYCU product
Product Rights Agreement
RPA
DEXYCU
Collaborative research and development
Product sales license and collaboration revenue or royalty income
Details
Date
DEXYCU product
Product Rights Agreement
RPA
DEXYCU
Collaborative research and development
Product sales license and collaboration revenue or royalty income
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
135,000.00 USD
0.00 USD
Jan 1, 2020
6.95 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
18.35 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
11.58 M USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
37.10 M USD
1.10 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
15.90 M USD
12.70 M USD
0.00 USD
0.00 USD
0.00 USD

EyePoint Revenue by Segment (4/5)

  • 3 Years

  • 5 Years

  • Max

RPA
Royalty purchase agreement
Technical Assistance
Collaborative Research and Development
Details
Date
RPA
Royalty purchase agreement
Technical Assistance
Collaborative Research and Development
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
255,000.00 USD
Jan 1, 2021
0.00 USD
872,000.00 USD
499,000.00 USD
60,000.00 USD
Jan 1, 2022
868,000.00 USD
0.00 USD
188,000.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD

EyePoint Revenue by Segment (5/5)

  • 3 Years

  • 5 Years

  • Max

DEXYCU product
YUTIQ product
Collaborative research and development
Royalty
Details
Date
DEXYCU product
YUTIQ product
Collaborative research and development
Royalty
Jan 1, 2018
0.00 USD
0.00 USD
1.10 M USD
1.00 M USD
Jan 1, 2019
4.78 M USD
12.05 M USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD

EyePoint Revenue by Region

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Country US
United States
China
G B
UNITED KINGDOM
Details
Date
Country US
United States
China
G B
UNITED KINGDOM
Jan 1, 2017
0.00 USD
7.44 M USD
0.00 USD
0.00 USD
100,000.00 USD
Jan 1, 2018
0.00 USD
2.86 M USD
0.00 USD
0.00 USD
100,000.00 USD
Jan 1, 2019
19.14 M USD
0.00 USD
1.12 M USD
0.00 USD
100,000.00 USD
Jan 1, 2020
22.62 M USD
0.00 USD
11.71 M USD
0.00 USD
100,000.00 USD
Jan 1, 2021
35.99 M USD
0.00 USD
851,000.00 USD
0.00 USD
100,000.00 USD
Jan 1, 2022
40.48 M USD
0.00 USD
823,000.00 USD
0.00 USD
100,000.00 USD
Jan 1, 2024
42.05 M USD
0.00 USD
1.12 M USD
0.00 USD
100,000.00 USD
Jan 1, 2025
29.98 M USD
0.00 USD
1.29 M USD
0.00 USD
100,000.00 USD

EyePoint Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

EyePoint historical P/E ratio, EBIT multiple, and P/S ratio

EyePoint annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

EyePoint shares outstanding

The number of shares of EyePoint was 56.3 M in 2025. This indicates how many shares EyePoint is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
12.84 M Stocks
Jan 1, 2021
28.76 M Stocks
Jan 1, 2022
37.32 M Stocks
Jan 1, 2023
38.90 M Stocks
Jan 1, 2024
56.30 M Stocks
Jan 1, 2025 (e)
56.30 M Stocks
Jan 1, 2026 (e)
56.30 M Stocks
Jan 1, 2027 (e)
56.30 M Stocks

EyePoint stock splits

In EyePoint's history, there have been no stock splits.

Current EyePoint forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy94.44 % (17)
Hold5.56 % (1)
Sell0.00 % (0)
12M Price Target
33.66
Last Price
14.72
Currency
USD
12M Return Potential
128.67 %
LTM Return
0 %

EyePoint Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/6/2026-0.81USD359,886.00USD2026 Q1
5/5/2026-0.81USD359,886.00USD2026 Q1
3/5/2026-0.76USD1.03 MUSD2025 Q4
3/4/2026-0.76USD1.03 MUSD2025 Q4
3/3/2026-0.76USD1.03 MUSD2025 Q4
5/1/2024-0.47USD10.96 MUSD2024 Q1
2/29/2024-0.51USD9.43 MUSD2023 Q4
8/1/2023-0.75USD7.92 MUSD2023 Q2
5/2/2023-0.73USD7.41 MUSD2023 Q1
3/1/2023-0.63USD10.73 MUSD2022 Q4

EESG©

Eulerpool ESG Scorecard© for the EyePoint stock

50/100
6
Environment
94
Social
51
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

EyePoint shareholder structure

% Name
14.78738%
Cormorant Asset Management, LP
Cormorant Asset Management, LP
12.08585%
Suvretta Capital Management, LLC
Suvretta Capital Management, LLC
12.07858%
Adage Capital Management, L.P.
Adage Capital Management, L.P.
8.17116%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
7.57978%
Franklin Advisers, Inc.
Franklin Advisers, Inc.
6.75450%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
...

EyePoint Executives and Management Board

JD

Dr. Jay Duker

(66)

President, Chief Executive Officer, Director · since 2016

Compensation5.95 M USD
RR

Mr. Ramiro Ribeiro

(42)

Chief Medical Officer

Compensation3.53 M USD
GE

Mr. George Elston

(60)

Chief Financial Officer, Executive Vice President

Compensation3.20 M USD
NL

Ms. Nancy Lurker

(67)

Executive Vice Chairman of the Board · since 2016

Compensation2.06 M USD
JL

Dr. John Landis

(72)

Non-Executive Independent Director

Compensation1.38 M USD

EyePoint Supply Chain

EyePoint Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
7 companies
#Name1M3M6M1Y2YTrend
1
AmerisourceBergen
-0.02
0.66
-0.42
0.21
0.61
2
McKesson
-0.54
0.68
-0.38
0.31
0.58
3
Harrow Health
Supplier
0.32
-0.31
0.38
-0.04
0.52
#Name1M3M6M1Y2YTrend
1
Ocumension
Supplier
-0.53
0.42
0.65
-0.35
—
2
Oncosil Medical
Supplier
-0.30
-0.04
0.13
-0.40
-0.69
3
Betta Pharmaceuticals A
Supplier
-0.42
-0.39
0.49
-0.25
-0.47
4
Alimera Sciences
Supplier
-0.07
0.29
0
-0.45
0.12

Frequently asked questions about EyePoint

EyePoint Pharmaceuticals Inc is a biopharmaceutical company specializing in the development and commercialization of innovative ophthalmic products. The business model of EyePoint Pharmaceuticals Inc revolves around developing sustained-release drug delivery systems for the treatment of serious eye diseases. By utilizing its proprietary technologies, the company aims to improve patients' outcomes by providing long-lasting and targeted drug delivery options. EyePoint Pharmaceuticals Inc focuses on developing and commercializing products addressing unmet medical needs, ultimately enhancing the quality of life for individuals suffering from various eye conditions.

All fundamentals and in-depth analysis of EyePoint

Our stock analysis for EyePoint stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyePoint. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

EyePoint Stock
EyePoint Revenue→
EyePoint Stock
EyePoint Net Income→
EyePoint Stock
EyePoint P/E→
EyePoint Stock
EyePoint P/S→
EyePoint Stock
EyePoint EBIT→
EyePoint Stock
EyePoint Dividend→
EyePoint Stock
EyePoint Directors Dealings→
EyePoint Stock
EyePoint Stocks→
EyePoint Stock
EyePoint Market capitalization→
EyePoint Stock
EyePoint Debt→
EyePoint Stock
EyePoint Liabilities→
EyePoint Stock
EyePoint Equity→
EyePoint Stock
EyePoint AAQS→
EyePoint Stock
EyePoint Employees→
EyePoint Stock
EyePoint ROE→
EyePoint Stock
EyePoint ROA→
EyePoint Stock
EyePoint ROCE→
EyePoint Stock
EyePoint News→
EyePoint Stock
EyePoint Analyst Price Targets→

Health Stocks

ezCaretech CoEyeGeneEZZ Life Science HoldingsEyeGate PharmaceuticalsF D CEyebright Medical Technology (Beijing) CoFabino EnterprisesExtendicareFaes FarmaExpreS2ion Biotech HoldingFagroneXoZymesAll Stocks A–Z →